Followers | 13 |
Posts | 1561 |
Boards Moderated | 0 |
Alias Born | 06/14/2018 |
![](https://investorshub.advfn.com/uicon/676580.png?cb=1690354813)
Wednesday, October 17, 2018 10:08:27 PM
Allogene: 2.8 billion - pipeline behind MRKR.
French company Cellectis: 1 billion - pipeline behind MRKR.
Allogene and Cellectis doing basically the same thing (off the shelf CAR-T).
Allogene is using technology that started at Cellectis that they got through Pfizer.
Pfizer owns about 25% of Allogene, and Gilead, who bought KITE also invested in Allogene.
So, you got 2 "off the shelf CAR-T" companies valued at about 4 billion, both with pipelines behind MRKR.
What are the advantages of "off the shelf CAR-T" technology that makes it valued so highly - it's much quicker and cheaper than let's say NON off the shelf CAR-T like KITE and JUNO and others do, plus it's also genetically engineered for that specific patient, also like KITE and JUNO and others do
Now compare MRKR MultiTAA technology - it is ALSO much quicker and cheaper, it is NOT genetically engineered, but that also makes it SAFER.
It also has some "proof" that it may even work "better".
So why, when MRKR pipeline is more advanced, is it valued so much lower?
For the last couple decades, biotech has been enamored by the next latest greatest new technology. We went from RNAI tech, to MRNA tech, to CAR-T tech, to TALON tech, to CRISPR tech.
ALL genetically engineered.
Along comes MRKR MultiTAA technology - quicker, cheaper, safer, better.
But it's not sexy, it's not NOW, it's not genetically engineered.
A couple of good trial results and it should just rocket ship, and you should hope that they do NOT accept a buy out by a Gilead or a Pfizer.
P.S. I'm as guilty as the rest of biotech. (RNAI tech) jumped on Alnylam early. Waited for YEARS for JUNO (CAR-T) to go public. Waited for YEARS for EDITAS (CRISPR) to go public. STILL waiting after YEARS for Moderna (MRNA) to go public.
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM